Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "3M"

30 News Found

KDAH receives SMART ICU certification after pandemic
News | September 23, 2022

KDAH receives SMART ICU certification after pandemic

Kokilaben Hospital is also the first hospital in Navi Mumbai to receive the SMART ICU certification


DAMAN enters ambitious European precision medicine healthcare project
News | September 21, 2022

DAMAN enters ambitious European precision medicine healthcare project

Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.


AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
Biotech | November 02, 2021

AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma

The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio


Indian Pharma Market witnesses rise in volumes and prices in September.
News | October 28, 2021

Indian Pharma Market witnesses rise in volumes and prices in September.

Acute therapies continue to report strong growth compared to chronic ones.


Zydus Cadila seeks approval for a two-dose ZyCoV-D Covid-19 vaccine
News | September 13, 2021

Zydus Cadila seeks approval for a two-dose ZyCoV-D Covid-19 vaccine

The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.


US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723
Drug Approval | August 31, 2021

US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723

The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers


Ajanta Pharma aims to file 10-12 ANDAs per annum
News | August 02, 2021

Ajanta Pharma aims to file 10-12 ANDAs per annum

India business is growing as per projections; whereas US business will bounce back soon.


Sun Pharmaceutical’s internals remain strong: ICICI Securities
News | May 31, 2021

Sun Pharmaceutical’s internals remain strong: ICICI Securities

US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio


Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
News | May 27, 2021

Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21

Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21


Steady performance; for Alkem Laboratories: ICICI Securities
News | February 13, 2021

Steady performance; for Alkem Laboratories: ICICI Securities

The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21